Helicobacter pylori News and Research

RSS

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that the independent Data Safety Monitoring Board (DSMB) for the global Phase 2/3 study of opaganib in patients with severe COVID-19, unanimously recommended to continue the study following a pre-scheduled futility review of unblinded efficacy data from the first 135 patients treated in the study and safety data from the first 175 patients.

30 Jan 2021

RedHill Biopharma: RHB-204 receives FDA Fast Track designation for treatment of NTM disease

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that RHB-204 has been granted Fast Track designation by the U.S. Food and Drug Administration for its development as a potential first-line, stand-alone, oral treatment of pulmonary nontuberculous mycobacteria (NTM) disease caused by Mycobacterium avium Complex (MAC) - a rare disease for which there is no FDA-approved first-line therapy.

6 Jan 2021

P2 COVID-19 study shows no material safety differences between opaganib and control arms

Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differences between opaganib and control arms.

4 Jan 2021

Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals

Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021. Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe COVID-19 expected in the coming days; this non-powered study was designed to evaluate safety and potential identification of preliminary efficacy signals in support of the global Phase 2/3 study of opaganib.

23 Dec 2020

RedHill Biopharma announces promising preliminary results from opaganib study

TEL AVIV, Israel and RALEIGH, NC, December 15, 2020, RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced promising preliminary results from a preclinical study with opaganib.

15 Dec 2020

Modulation of oral microbiota impacts the cardiovascular benefits of sport

Exercise plays a key role in maintaining good physical and mental health throughout life. There is an increasing amount of scientific evidence that some of the immune system and metabolism benefits provided by sport are related to the thousands of millions of bacteria that colonize the digestive tract, from the mouth to the intestines, known as microbiota.

9 Dec 2020

New reviews provide timely updates for scholars, professionals focused on antimicrobial research

The initial chapter of 'Anti-infective Research and Development: Updates on Infection Mechanisms and Treatments' covers the mode of action of natural antimycobacterial compounds such as nordihydroguaiaretic acid, α-mangostin and allicin, as well as antimicrobial peptides and their role in the innate and adaptive immune response leading to the decrease of microbial resistance.

1 Dec 2020

Scientists discover a novel antiviral strategy for treating COVID-19

A research team led by Professor Hongzhe SUN, Norman & Cecilia Yip Professor in Bioinorganic Chemistry, Department of Chemistry, Faculty of Science, and Professor Kwok Yung YUEN, Henry Fok Professor in Infectious Diseases, Department of Microbiology, Li Ka Shing Faculty of Medicine of the University of Hong Kong (HKU), has discovered a novel antiviral strategy for treatment of COVID-19.

16 Oct 2020

Small RNA molecule controls major pathogenicity factors of H. pylori

More than half of the world's population carries the bacterium Helicobacter pylori in their stomach mucosa. It often causes no problems throughout life, but sometimes it can cause inflammation, and in some cases, it can even lead to the development of stomach cancer.

15 Oct 2020

Spike ferritin nanoparticles show potential as SARS-CoV-2 vaccine

Now, a new study published on the preprint server bioRxiv* in August 2020 reports the induction of neutralizing antibodies in mice by a single dose of a ferritin nanoparticle-based vaccine containing the spike protein.

1 Sep 2020

Daily cranberry intake could reduce H. pylori infections

A new clinical trial found consuming cranberry juice containing 44 mg of proanthocyanidins (or "PACs") per 240-mL serving twice daily for eight weeks resulted in a 20% reduction in the H. pylori infection rate in Chinese adult participants, when compared to those consuming lower amounts of juice and a placebo.

18 Aug 2020

Tasmanian devil research provides new insights for treating human cancers in future

A rare, transmissible tumor has brought the iconic Tasmanian devil to the brink of extinction, but new research by scientists at Washington State University and the Fred Hutchinson Cancer Research Center in Seattle indicates hope for the animals' survival and possibly new treatment for human cancers.

6 Aug 2020

Blood type plays role in SARS-CoV-2 infection

A new meta-analysis from Iran, available on the medRxiv preprint server, showed that the blood group A could be considered a partial risk factor for infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), whereas the blood group O may act as a protective factor; conversely, no significant associations were observed between specific blood groups and coronavirus disease (COVID-19) mortality.

10 Jun 2020

Neuroscientists trace brain-to-gut pathways

Neuroscientists at the University of Pittsburgh Brain Institute have traced neural pathways that connect the brain to the stomach, providing a biological mechanism to explain how stress can foster ulcer development.

18 May 2020

MicroRNA dysregulation has critical impacts on development, inflammation and cancer development

Oncotarget Volume 11, Issue 10 reported that dysregulation of noncoding micro RNA molecules has been associated with immune cell activation in the context of Helicobacter pylori-induced gastric inflammation as well as carcinogenesis, but also with downregulation of mismatch repair genes, and may interfere with immune checkpoint proteins that lead to the overexpression of antigens on gastric tumor cells.

13 Mar 2020

First comprehensive survey of viruses found within different cancers

Researchers from the University of East Anglia have helped to carry out the first comprehensive survey of viruses found within different types of cancer.

5 Feb 2020

Study uncovers how common stomach bacterium maintains its corkscrew-like shape

A new study shows how a common stomach bacterium is able to keep its corkscrew-like shape as it grows. Disrupting the shape could point the way for future, more-specialized antibiotics that prevent the bacterium from being harmful.

23 Jan 2020

Study reveals new mechanism that controls the causes of stomach disease

Infectious diseases triggered by bacteria and other microbes are the most frequent cause of human mortality across the globe.

8 Jan 2020

AGA publishes clinical guideline for managing patients with gastric intestinal metaplasia

Gastric intestinal metaplasia (GIM), which is linked to non-cardia gastric cancer, is often detected during routine endoscopy, leading to questions about how patient care should be managed.

10 Dec 2019

Eradicating H pylori infection significantly reduces gastric cancer risk

While it is well known within the medical community that there is a link between the bacteria Helicobacter pylori (H pylori) and rates of gastric cancer- commonly referred to as stomach cancer - the rates and risk among Americans has been largely understudied.

14 Nov 2019